May 5, 2022
Aravax appoints Dr Brett Haumann to Board of Directors
06 May 2022, Melbourne, AUSTRALIA: Aravax, a clinical stage biotechnology company focused on developing the most advanced novel therapy...
top of page
Developing safe, convenient, disease-modifying treatments for food allergies.
.jpg)
News
bottom of page